



11/05/99

Docket No. 88-98

11/05/99

PATENT APPLICATION TRANSMITTAL LETTER

To the Commissioner of Patents and Trademarks:

Transmitted herewith for filing under 35 U.S.C. 111 and 37 C.F.R. §1.53 is the patent application of:
John S. Lollar

entitled:

**GLYCOSYLATED, LOW ANTIGENICITY
LOW IMMUNOGENICITY FACTOR VIII**

Enclosed are:

- ☒ 7 pages of written description, claims and abstract.
☐ sheets of drawings.
☐ sequence listing - paper copy
☐ an assignment of the invention to _____.
☐ executed declaration of the inventors and associate power of attorney.
☐ a certified copy of a _____ application.
☐ a verified statement to establish small entity status under 37 CFR §1.9 and §1.27.
☐ information disclosure statement.
☐ preliminary amendment
☒ other: Sequence Listing Diskette
☒ Statement under 37-CFR § 1-821-824

CLAIMS AS FILED

	Number Filed	Number Extra*	Rate	Fee
BASIC FEE			\$760	\$760
TOTAL CLAIMS	1-20 =	0	x \$18	
INDEPENDENT CLAIMS	1-3 =	0	x \$78	
MULTIPLE DEPENDENT CLAIM PRESENT			x \$260	

* Number extra must be zero or larger **TOTAL \$760.00**

If applicant has small entity status under 37 C.F.R. 1.9 and 1.27, then divide total fee by 2, and enter amount here.	
SMALL ENTITY TOTAL	\$

The PTO did not receive the following
listed item(s) Sequence Listing Dis-
Kette

X

No filing fee is enclosed at this time.

—

A check in the amount of \$_____ to cover the filing fee is enclosed.

—

The Commissioner is hereby authorized to charge and credit Deposit Account No. 07-1969 as described below.

—

Charge the amount of \$_____ as filing fee.

—

Credit any overpayment.

—

Charge any additional filing fees required under 37 CFR 1.16 and 1.17.

—

Charge any processing fees required under 37 CFR 1.17

—

Charge the issue fee set in 37 CFR 1.18 at the mailing of the Notice of

—

Allowance, pursuant to 37 CFR 1.311(b).

—

Other _____

—

Benefit of Prior U.S. Application(s) (35 USC 119)

Applicant claims priority under 35 USC 119 to the following application(s):

U.S. Provisional Patent Application Serial No. 60/107,402, filed November 6, 1998.

Lorance L. Greenlee

SIGNATURE OF ATTORNEY

Reg. No. 27,894

Lorance L. Greenlee

Type or print name of attorney

GREENLEE, WINNER AND SULLIVAN, P.C.

5370 Manhattan Circle, Suite 201

Boulder, Colorado 80303

Telephone No. (303) 499-8080

Facsimile No. (303) 499-8089

Email: winner@greenwin.com

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as EXPRESS MAIL in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

5 November 1999 B. Kroge

Date B. Kroge

Express Mail Receipt No: EL 416 876 771 US

APPLICATION FOR LETTERS PATENT

Inventor:

John S. Lollar

GLYCOSYLATED, LOW ANTIGENICITY LOW IMMUNOGENICITY FACTOR VIII

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as "Express Mail" in an envelope addressed to Assistant Commissioner for Patents.

5 November 1999 B. Kroge
Date B. Kroge
Express Mail Receipt el 416 876 771 US

Prepared by:

GREENLEE, WINNER AND SULLIVAN, P.C.
5370 Manhattan Circle
Suite 201
Boulder, Colorado 80303
(303) 499-8080
FAX: (303) 499-8089

Attorney Docket Number 88-98

GLYCOSYLATED, LOW ANTIGENICITY, LOW IMMUNOGENICITY FACTOR VIII

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority from United States Provisional Patent Application No. 60/107,402, filed November 6, 1998.

BACKGROUND OF THE INVENTION

Hemophilia A is defined as hereditary deficiency of blood coagulation fVIII. FVIII is synthesized as a ≈ 300 kDa single chain protein with internal sequence homology that defines the "domain" sequence $\text{NH}_2\text{-A1-A2-B-A3-C1-C2-COOH}$ (Fig. 1) $\langle \{\{33\}\} \rangle$. Domains are commonly delineated as A1 (Ala1-Arg372), A2 (Ser373-Arg740), B (Ser741-Arg1648), and A3-C1-C2 (Ser1690-Tyr2332) $\langle \{\{398\}\} \rangle$. Despite its large size, the B domain of fVIII has no known function and can be deleted $\langle \{\{11\}\} \rangle$. FVIII is measured by its ability to correct the prolonged clotting time of plasma prepared from patients with hemophilia A.

Hemophilia A, which is due to fVIII deficiency, is an X-linked, recessive disorder that is the most common severe, hereditary bleeding disorder in man. The mainstay of management of hemophilia A is fVIII replacement therapy by intravenous infusion. Current products in the marketplace include recombinant fVIII, immunoaffinity-purified plasma-derived fVIII, and intermediate-purity plasma-derived fVIII.

The development of inhibitory antibodies (inhibitors) to fVIII is a serious complication in the management of patients with hemophilia A. Alloantibodies develop in approximately 25% of patients with hemophilia A in response to therapeutic infusions of fVIII $\langle \{\{2193\}\} \rangle$. In previously untreated patients with hemophilia A who develop inhibitors, the inhibitor usually

develops within one year of treatment <{{2105}}>, although it can occur at any time <{{2137}}>. Additionally, autoantibodies that inactivate fVIII can occur in non-hemophiliacs in a variety of clinical settings including the postpartum period, in systemic lupus erythematosus, in chronic lymphocytic leukemia, and in elderly females. This condition is called acquired hemophilia.

FVIII inhibitors are measured clinically by the ability of the patient's plasma to inhibit fVIII in normal plasma. The standard test is the Bethesda assay <{{1806}}>. One Bethesda unit is defined as the dilution of patient plasma required to reduce the fVIII level by 50%.

A molecule is said to be *antigenic* when it binds to antibodies and *immunogenic* when it can induce an immune response <{{1895}}>. The immunogenicity of a molecule depends on the B cell repertoire, T cell help and suppression, and the major histocompatibility complex, which together determine the concentration and binding affinity of antibodies for an antigenic site. If a fVIII molecule could be constructed that did not bind to the inhibitory antibodies in a patient's plasma, it would be useful therapeutically. Additionally, if a fVIII molecule could be constructed that is less immunogenic than wild-type human fVIII, i.e., could significantly lower the 25% incidence of inhibitor development, it would be safer than wild-type human fVIII. This molecule would have general applicability in the hemophilia A population.

Inhibitory antibodies to fVIII bind to either the A2, A3, or C2 domains of fVIII and disrupt specific functions associated with these domains <{{57,595,1803}}>. The A2 epitope is located within a linear sequence bounded by residues Arg484-Ile508 <{{2054}}>. The C2 epitope has been localized to a sequence bounded by residues Glu2181-Val2243 <{{2574}}>. The A3 epitope has not yet been mapped. The fact that fVIII epitopes are limited in number and can be mapped to the amino acid sequence level makes it possible to design strategies to produce low antigenicity and low immunogenicity fVIII molecules. We have already reduced the antigenicity of fVIII by replacing epitopes with non-human fVIII sequences <{{1824,2054,2574}}> and by site-directed mutagenesis of amino acids within fVIII epitopes <{{2343}}>.

Viruses, such as the human immunodeficiency virus (HIV), elude the immune system by varying epitopes that are recognized by antibodies <{{2573}}>. HIV contains an exterior envelope glycoprotein, gp120, which is targetted by the immune system in its attempts to rid the body of virus. HIV reduces the immunogenicity of gp120 using a post-translational process in which a polysaccharide is linked to asparagine residues. This process is called N-linked glycosylation because N is the single letter code for the amino acid asparagine. When the immune system makes antibodies to the existing glycosylated epitope, HIV responds by mutation vary its N-linked glycosylation sites. This reduces the immunogenicity of the virus. Similarly, the immunogenicity of fVIII could be reduced by altering the epitope by glycosylation. Additionally, the structure recognized by existing antibodies would be altered, reducing the antigenicity of the molecule.

SUMMARY OF THE INVENTION

The fVIII cDNA is modified to code for amino acids within known, existing epitopes to produce a recognition sequence for glycosylation at asparagine residues. The consensus amino acid sequence for N-linked glycosylation is N-X-S/T, where N is asparagine, X is any amino acid, S/T stands for serine and threonine. Modification of the cDNA is accomplished by site-directed mutagenesis using standard methods. Thus, any three residue sequence in fVIII can be altered to N-X-S/T to produce the desired recognition site. Alternatively, a sequence containing a serine or threonine can be altered by mutating a single site to asparagine to produce the desired N-X-S/T sequence.

The fVIII cDNA is inserted into a mammalian expression vector, which then is stably integrated into the genome of a mammalian host cell in culture. FVIII is secreted into the cell culture medium and purified. It is tested for antigenicity by measuring whether it is inhibited by inhibitory antibodies to fVIII that are obtained from patients. It is tested for immunogenicity by infusing it into hemophilia A mice and determining whether inhibitory antibodies develop.

DETAILED DESCRIPTION OF THE INVENTION

As an example of the method used to create glycosylated, low antigenicity, low immunogenicity fVIII, we describe the introduction of a recognition site for N-linked glycosylation at leucine 486 within the A2 epitope. FVIII contains a serine at position 488 within the A2 epitope. The 486-488 sequence is leu-tyr-ser. Therefore, mutation of leucine to asparagine produces a sequence N-Y-S (using the single letter code), which is a recognition site for N-linked glycosylation.

This mutation was introduced by site-directed mutagenesis of the human B-domainless fVIII cDNA. The cDNA sequence corresponding to residues 484-508 is shown in the Table. The DNA sequence is SEQ ID NO:1; the translated, unmodified amino acid sequence is SEQ ID NO:2.

484	AAC														
CGT	CCT	TTG	TAT	TCA	AGG	AGA	TTA	CCA	AAA						
R	P	L	Y	S	R	R	L	P	K						
										508					
GGT	GTA	AAA	CAT	TTG	AAG	GAT	TTT	CCA	AAT	CTG	CCA	GGA	GAA	ATA	
G	V	K	H	L	K	D	F	P	I	L	P	G	E	I	

The nucleotide sequence TTG, coding for leucine, was changed to AAC, which codes for asparagine.

The fVIII mutant cDNA, contained in the mammalian expression vector ReNeo <{{1824}}>, was transfected into COS-7 monkey cells for initial characterization. It was then stably transfected into baby hamster kidney cells using geneticin selection as described previously <{{1824,2054}}>. The transformed cells expressed active fVIII, in this instance, human B-domainless L486N factor VIII.

As a further example, an N-linked glycosylation site was introduced into the C2 epitope. DNA encoding glutamine 2189 was mutated to encode asparagine, generating an asparagine-isoleucine-threonine amino acid sequence which is a recognition site for glycosylation at amino acid residue 2189.

5

It will be understood by those skilled in the art that other such modifications can be made within any of the domains giving rise to inhibitory analogs to provide N-linked glycosylation sites. Further, a plurality of such sites can be combined in a single fVIII molecule, so as to render the molecule unreactive (or less active than wild-type) to inhibitory antibodies. FVIII molecules modified according to this invention are also expected to have reduced immunogenicity.

10

CLAIMS:

1. A method for preparing a factor VIII having modified glycosylation comprising the steps of

mutating a desired segment of factor VIII DNA to encode -N-X-S/T, where N is asparagine, X is any amino acid and S/T is serine or threonine, thereby providing mutated factor VIII DNA encoding a post-translational glycosylation site at the desired locus of factor VIII proten, and

expressing the mutated DNA in a host cell capable of post-translational glycosylation, whereby factor VIII having modified glycosylation is prepared.

ABSTRACT

The development of inhibitory antibodies to blood coagulation factor VIII (fVIII) results in a severe bleeding tendency. These antibodies arise in patients with hemophilia A (hereditary fVIII deficiency) who have been transfused with fVIII. They also occur in non-hemophiliacs, which produces the condition acquired hemophilia. We describe a method to construct and express novel recombinant fVIII molecules which escape detection by existing inhibitory antibodies (low antigenicity fVIII) and which decrease the likelihood of developing inhibitory antibodies (low immunogenicity fVIII).

In this method, fVIII is glycosylated at sites that are known to be antibody recognition sequences (epitopes). This produces the desired properties of low antigenicity fVIII and low immunogenicity fVIII. The mechanism is similar to one used by viruses such as the AIDS virus, which glycosylates its surface proteins to escape detection by the immune system.